ABBOTT INDIA LIMITED
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 138
- Registration Number
- NCT00234923
A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2007-10-25
- Lead Sponsor
- Abbott
- Target Recruit Count
- 380
- Registration Number
- NCT00234949
Quality of Life Study With Adalimumab in Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2007-10-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 200
- Registration Number
- NCT00234936
Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2007-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1938
- Registration Number
- NCT00234897
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-11-21
- Lead Sponsor
- Abbott
- Target Recruit Count
- 200
- Registration Number
- NCT00234962
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 280
- Registration Number
- NCT00234858
A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 93
- Registration Number
- NCT00234988
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 357
- Registration Number
- NCT00234871
Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-07-10
- Lead Sponsor
- Abbott
- Target Recruit Count
- 120
- Registration Number
- NCT00235001
- Locations
- 🇺🇸
Global Medical Information-Abbott, North Chicago, Illinois, United States
Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2007-04-24
- Lead Sponsor
- Abbott
- Target Recruit Count
- 160
- Registration Number
- NCT00233558
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
© Copyright 2024. All Rights Reserved by MedPath